BeOne Medicines (ONC) Stock May Be Rich After BRUKINSA Access Renewal

BeOne Medicines stock has produced a strong 85.8% return over the past three years, yet the current valuation checks and market multiples suggest the shares are not an obvious bargain at today’s price.

• The 85.8% three year return signals that BeOne Medicines has already delivered substantial gains for long term holders, so fresh capital is now facing a very different entry point.
• Recent agreements to expand access to BRUKINSA and to collaborate on RAS inhibitor development can support long term revenue potential. However, execution risk on these partnerships and the cost of further oncology development may weigh on what investors are willing to pay.
• With a low value score and only 2 of 6 valuation checks screening as attractive, BeOne Medicines currently leans expensive rather than clearly undervalued.

The issue now is whether BeOne Medicines’ recent progress in oncology and access programs is enough to justify paying this kind of premium for the stock.

Find out why BeOne Medicines' 21.8% return over the last year is lagging behind its peers.

Does BeOne Medicines Look Pricey on Earnings?

The P/E ratio is a useful yardstick for BeOne Medicines because earnings are a key driver of long term value for a commercial stage biotech group. On this measure, BeOne Medicines trades on a P/E of 65.3x, which is well above the Biotechs industry average of 17.8x and also ahead of the broader peer set at 28.6x. That already places the stock on a rich earnings multiple compared with many listed biotech companies.

The company’s fair P/E ratio is estimated at 34.8x, which reflects what investors might typically pay given its growth profile, profitability, size and risk. The gap from this fair level to the current 65.3x suggests the stock is pricing in a lot of optimism about future earnings. Despite the recent BRUKINSA access renewal and the RAS inhibitor collaboration, the earnings multiple still points to BeOne Medicines trading at a premium rather than a discount.

Overall, BeOne Medicines stock appears expensive on its current P/E multiple relative to both its fair ratio and sector benchmarks.

See what the numbers say about this price — find out in our valuation breakdown.

The BeOne Medicines Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for BeOne Medicines pick up where the valuation puzzle leaves off by spelling out which assumptions on future growth, margins and earnings would need to hold for BeOne Medicines' stock to be worth materially more or materially less than it is today. Rather than relying on a single multiple or model output, each one sets out the assumptions behind its fair value so you can later compare them with the results the company actually reports.

Community views on BeOne Medicines are pulled in opposite directions, with one camp seeing underappreciated oncology breadth and another focused on concentration and policy risk.

Bull case: 24% undervalued

"BeOne's highly differentiated next-generation targeted oncology portfolio, bolstered by synergistic combinations and strategic late-stage pipeline assets like sonrotoclax and BTK CDAC, positions the company not only for first-mover advantage in numerous indications but also for premium pricing and margin expansion as these assets gain approvals and market traction…"

Read the full Bull Case to see why BeOne Medicines could be undervalued

Bear case: 10% overvalued

"BeOne Medicines is heavily reliant on BRUKINSA as its primary revenue driver; any loss of exclusivity due to patent cliffs or accelerated approval of biosimilars and generics will likely result in sharp revenue declines, heightened earnings volatility, and potential net margin compression as competition intensifies in key indications…"

Read the full Bear Case to see why BeOne Medicines could be overvalued

Do you think there's more to the story for BeOne Medicines? Head over to our Community to see what others are saying!

The Bottom Line

For BeOne Medicines, the valuation work points to a stock that currently screens as overvalued on market multiples. A high P/E relative to peers suggests investors are already paying up for the oncology pipeline and partnership story. From here, the key question is whether future earnings and margins from BRUKINSA and the RAS franchise ultimately justify that premium or whether expectations need to cool. The crux of the bull versus bear debate is how much confidence you place in BeOne Medicines turning its pipeline breadth into durable, less concentrated cash flows.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com